Literature DB >> 2737225

Acute haemodynamic effects of different doses of alifedrine in congestive heart failure.

I S Anand1, L O Hughes, J R Whittington, E B Raftery.   

Abstract

The haemodynamic effects of single oral doses of alifedrine 40 mg, 50 mg, 60 mg and placebo were compared in 30 patients with mild to moderate heart failure. Individual patients received either alifedrine 60 mg and placebo (15 patients) or alifedrine 40 mg and 50 mg (15 patients). All doses of alifedrine produced qualitatively similar haemodynamic responses, with maximum changes between 90 and 180 min after drug administration. The cardiac index was increased by +39%, +57%, and +50% by 40 mg, 50 mg and 60 mg, respectively. The increases were due to rises in stroke volume index (SVI) and in heart rate of +15%, +20% and +23%. Mean arterial blood pressure fell in a dose-related fashion, with a maximum fall of 11% by 120 min after 60 mg. The systemic vascular resistance index (SVRI) fell by 28%, 39% and 41%, and pulmonary vascular resistance index (PVRI) by 32%, 44% and 32% after 40 mg, 50 mg and 60 mg, respectively. The optimum dose appears to be 40 mg, which caused very little fall in blood pressure or increase in heart rate, yet significantly improved cardiac output. Alifedrine may have a place in the treatment of heart failure as an oral by active, positive inotropic agent.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2737225     DOI: 10.1007/bf00558291

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

Review 1.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1.

Authors:  W S Colucci; R F Wright; E Braunwald
Journal:  N Engl J Med       Date:  1986-01-30       Impact factor: 91.245

2.  Should the failing heart be stimulated?

Authors:  T H LeJemtel; E H Sonnenblick
Journal:  N Engl J Med       Date:  1984-05-24       Impact factor: 91.245

Review 3.  Vasodilator therapy of cardiac failure: (first of two parts).

Authors:  J N Cohn; J A Franciosa
Journal:  N Engl J Med       Date:  1977-07-07       Impact factor: 91.245

Review 4.  Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts.

Authors:  R R Miller; A R Palomo; T A Brandon; C J Hartley; M A Quinones
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

5.  Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.

Authors:  M Packer; N Medina; M Yushak
Journal:  Circulation       Date:  1984-12       Impact factor: 29.690

6.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

7.  Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.

Authors:  D S Baim; A V McDowell; J Cherniles; E S Monrad; J A Parker; J Edelson; E Braunwald; W Grossman
Journal:  N Engl J Med       Date:  1983-09-29       Impact factor: 91.245

8.  Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.

Authors:  W S Colucci; R F Wright; B E Jaski; M A Fifer; E Braunwald
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

9.  Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.

Authors:  P K Shah; D K Amin; S Hulse; F Shellock; H J Swan
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690

10.  Combined dopamine and nitroprusside therapy in congestive heart failure. Greater augmentation of cardiac performance by addition of inotropic stimulation to afterload reduction.

Authors:  R R Miller; N A Awan; J A Joye; K S Maxwell; A N DeMaria; E A Amsterdam; D T Mason
Journal:  Circulation       Date:  1977-06       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.